Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK F1174C |
Therapy | Alectinib |
Indication/Tumor Type | prostate small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK F1174C | prostate small cell carcinoma | predicted - sensitive | Alectinib | Case Reports/Case Series | Actionable | In a clinical case report, Alecensa (alectinib) treatment in a patient with prostate small cell carcinoma harboring ALK F1174C resulted in stable disease and a decrease in ALK F1174C allele fraction in circulating tumor DNA, with clinical benefit ongoing after 7 months (PMID: 29559559). | 29559559 |
PubMed Id | Reference Title | Details |
---|---|---|
(29559559) | Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib. | Full reference... |